|8 August 2014
||Final report published
|End of July 2014
||Final deadline for all parties’ responses/submissions
|Late July – August 2014
||Remedies hearing(s) (if required)
||Notifying provisional findings and considering possible remedies
|Mid June 2014
||Deadline for all parties’ responses/submissions required before provisional findings
||Main party hearings
|May – June 2014
||Verify information, consider provisional findings
|Mid April 2014
||Publish a statement of issues
||Third party hearings.
|March – May 2014
||Gathering information, issuing questionnaires.
|14 March 2014
||Phase 2 merger reference made
|20 May 2014
|14 March 2014
|16-27 January 2014
||Invitation to comment
|15 January 2014
||Launch of merger enquiry
Final report published
On 8 August 2014, the CMA published its final report into the anticipated acquisition by Omnicell, Inc./MTS Medication Technologies, Inc. of SurgiChem Limited. The CMA cleared the proposed acquisition for the reasons set out in the report below:
On 11 July 2014, the CMA published its provisional findings into the anticipated acquisition by Omnicell, Inc./MTS Medication Technologies, Inc. of SurgiChem Limited. The CMA provisionally cleared the proposed acquisition for the reasons set out in the summary and full report below. Any interested party is now invited to respond to the provisional findings as set out in the notice of provisional findings.
CMA commissioned research and survey
Third party hearing summaries
Between April to May 2014
Between March to May 2014
In this statement we set out the key issues that we are likely to consider in reaching our decision. This does not preclude the consideration of any other issues that may be identified in the course of our inquiry.
Inquiry group members appointed
Appointed on 25 March 2014
Roger Witcomb (chairman), Marisa Cassoni, Michael Hutchings, Jill May
Merger reference made to the CC
OFT reference decision
The decision in this case was announced on 14 March 2014. The full text of the decision is available below:
The OFT is considering whether arrangements are in progress or in contemplation which, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
Launch of OFT merger inquiry
The OFT launched its merger inquiry following receipt of a satisfactory submission on 15 January 2014.
To respond to the notice of provisional findings, please email firstname.lastname@example.org or write to:
Omnicell/Surgichem merger inquiry
Competition and Markets Authority